2 research outputs found

    Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

    No full text

    Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

    No full text
    corecore